BD Diagnostic Systems, Sparks, MD, announces the immediate availability of BBL™ CHROMagar™ Salmonella , a chromogenic selective and differential medium for the presumptive identification of Salmonella species in foods. Unlike traditional media, BBL CHROMagar Salmonella does not detect Salmonella based upon H2S or glucuronidase production, or on non-lactose fermentation. This unique BBL formulation allows Salmonella species to produce mauve (rose to purple) colonies that are easily differentiated from other bacteria, including coliforms, which may resemble Salmonella on other traditional media. Laboratorians will be able to perform fewer subcultures and biochemical tests as compared to conventional media.
An expert independent laboratory tested BBL CHROMagar Salmonella to evaluate recovery of Salmonella compared to the reference USDA FSIS, FDA BAM and ISO media, as required by the AOAC Research Institute (RI) Performance Tested Methods program. BBL CHROMagar Salmonella had 100% agreement with all three reference methods when using a variety of food types, including raw ground beef, raw chicken, raw fish, lettuce and shell eggs. BBL CHROMagar Salmonella showed a high level of sensitivity and specificity compared to traditional media. The results of this study demonstrate that BBL CHROMagar Salmonella is an effective alternative to current standard reference media for the isolation and presumptive identification of Salmonella in a variety of foods.
BBL CHROMagar Salmonella is the first formulation in the BBL CHROMagar family of products to receive AOAC-RI approval. The BBL CHROMagar family of products also includes BBL™ CHROMagar™ Orientation , BBL™ CHROMagar™ Candida , BBL™ CHROMagar™ Staph aureus , BBL™ CHROMagar™ O157 , BBL™ CHROMagar™ Listeria , and BBL™ CHROMagar™ MRSA. For more information on BBL CHROMagar Salmonella, please call 1-800-638-8663, or contact your local BD Diagnostic Systems representative.
All trademarks are the property of Becton, Dickinson and Company, except CHROMagar, which is a trademark of Dr. A. Rambach. AOAC-RI is a trademark and Performance Tested is a service mark of AOAC International. © 2005 BD.
This press release may contain certain forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, products and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. Factors that could cause actual results to vary materially from any forward-looking statement include, but are not limited to: competitive factors; pricing and market share pressures; changes in interest or foreign currency exchange rates; difficulties inherent in product development and delays in product introductions; changes in regional, national or foreign economic conditions; increases in energy costs; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; and changes in healthcare or other governmental regulation; issuance of new or revised accounting standards, as well as other factors discussed in this press release and in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.
